Beijing Kawin Technology Share-Holding Full Year 2023 Earnings: Revenues Disappoint

Beijing Kawin Technology Share-Holding (SHSE:688687) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥1.41b (up 22% from FY 2022).
• Net income: CN¥116.1m (up 39% from FY 2022).
• Profit margin: 8.2% (up from 7.2% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: CN¥0.69 (up from CN¥0.49 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Kawin Technology Share-Holding Revenues Disappoint

Revenue missed analyst estimates by 3.7%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 9.1% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Beijing Kawin Technology Share-Holding (1 is potentially serious!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.